It is made available under a CC-BY-NC-ND 4.0 International license .

1 Research Article

2 Title: Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in
 3 Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Authors: Leticia R. Cruz^{1*}, Idania Baladrón^{2*}, Aliusha Rittoles¹, Pablo A. Díaz², Carmen
Valenzuela³, Raúl Santana¹, Maria M. Vázquez², Ariadna García¹, Deyli Chacón¹, Delvin
Thompson¹, Gustavo Perera¹, Ariel González⁴, Rafael Reyes⁵, Loida Torres⁴, Jesus
Pérez¹, Dania M. Vázquez², Gilda Lemus², Mauro Rosales^{2,6}, Ailyn C. Ramón², George
V. Perez², Gerardo Guillén², Verena Muzio², Yasser Perera^{2,7}, and Silvio E. Perea² for the
ATENEA-Co-300 group⁴

10 * These authors contributed equally to this work

11 Affiliations:

- 12 1. Central Hospital "Luis Diaz Soto", Havana 19130, Cuba
- 13 2. Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba
- 14 3. Center for Molecular Immunology, Havana 11600, Cuba
- 15 4. International Center of Health "La Pradera", Havana 11600, Cuba
- 16 5. National Institute of Oncology and Radiobiology, Havana 10400, Cuba
- 17 6. Faculty of Biology, University of Havana, Havana 10400, Cuba
- China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu
 Biotechnology Co., Ltd, Yangjiaqiao Street, Lengshuitan District, Yongzhou City, Hunan
 425000, China

21 **Corresponding Author:**

- 22 Silvio E. Perea, PhD, Prof (<u>silvio.perea@cigb.edu.cu</u>)
- 23 Head of the Molecular Oncology Group
- 24 Biomedical Research Area
- 25 Center for Genetic Engineering and Biotechnology
- 26 Havana 10600, Cuba
- 27 Number of Figures: 2
- 28 Number of Tables: 5
- 29 Keywords: Covid-19, Coronavirus infection, SARS-Cov2, Protein Kinase CK2, CIGB-325

It is made available under a CC-BY-NC-ND 4.0 International license .

30 Abstract

Background: The recently discovered instrumental role of CK2 in the SARS-Cov2 infection has pointed out this protein kinase as a promising therapeutic target in Covid-19 disease. Accordingly, anti-SARS-Cov2 activity has been reported by CK2 inhibitors *in vitro*, however any anti-CK2 clinical approach has been assessed in Covid-19 patients so far. Here, we investigated the putative clinical benefit of CIGB-325, an anti-CK2 peptide previously used in cancer patients, which was added to the standard-of- care to treat Covid-19.

38 Methods: A monocentric, randomized standard-of-care controlled trial of intravenous 39 CIGB-325 in adults hospitalized with Covid-19. Twenty patients were randomly assigned 40 to receive CIGB-300 (2.5 mg/kg/day during 5-consecutive days) plus standard-of-care 41 (10 patients) or standard-of-care (10 patients). Primary outcomes were time to viral 42 clearance defined as the time (in days) to have nasopharyngeal SARS-Cov2 negative PCR 43 and clinical response. This trial is registered with https://rpcec.sld.cu/trials/RPCEC00000317-En (Code: IG/CIGB300I/CV/2001). 44

45 **Results:** Most of the patients had initial positive by chest-computed tomography (CT). 46 CIGB-325 treatment reduced both number of pulmonary lesions and lesion's extent 47 compared to control group in seven days. Taking into account the Covid-19 chest-CT 48 abnormalities, CIGB-325 was also superior to control as well as in terms of proportion of 49 patients with such clinical benefit. Improvement of clinical status was experienced in 50% of patients in the CIGB-325 group and 25% in control. Accordingly, systemic levels 50 51 of CPK, LDH and CRP were lowered at day 7 by treating with this anti-CK2 peptide. 52 Both therapeutic regimens were similar respect to SARS-Cov2 clearance in nasopharynx 53 swabs over the time.

54 Conclusion: Our study revealed that consecutive-5 day regimen of intravenous CIGB-

55 325 at 2.5 mg/kg quickly improved the chest-CT outcomes over standard-of-care. This is

the first report describing signs of clinical benefit of an anti-CK2 approach in Covid-19.

It is made available under a CC-BY-NC-ND 4.0 International license .

57 Introduction

58 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide 59 and has infected nearly 20 million people [1, 2]. Many infected people are asymptomatic 60 or experience mild symptoms and recover without medical intervention [3, 4]. However, older people and those with comorbid hypertension, diabetes, obesity, and heart disease 61 62 are at higher risk of life-threatening illness [5, 6]. Therefore, development of an effective antiviral drug for COVID-19 is a global health priority. Along with the development of 63 new antiviral drugs, repurposing existing drugs for COVID-19 treatment is also 64 65 accelerated [7]. Some antiviral drugs have shown high efficacy against SARS-CoV-2 both in vitro [8] and in vivo models [9, 10]. A number of clinical studies such as 66 67 compassionate use programs and clinical trials have been conducted to test the efficacy of 68 FDA-approved drugs, such as lopinavir and ritonavir, chloroquine, favipiravir, and remdesivir (RDV) [11-14]. However, the results from those clinical studies were often 69 70 inconsistent and lacking of compelling evidences. More recently, a double-blind, 71 randomized, placebo-controlled trial of intravenous RDV in adults hospitalized with 72 Covid-19 and lower respiratory tract involvement had a median recovery time of 11 days 73 (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in 74 those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P < 75 0.001) [15].

At present, the main antiviral strategies currently employed against SARS-CoV-2 can broadly be divided into two types: strategies directly targeting the virus and strategies indirectly targeting the virus via host modulation [16]. In both strategies there are already-approved drugs and experimental candidates in Clinical trials [16]. Likewise, discovery of novel cellular targets for SARS-Cov2 coronavirus has led to novel putative clinical strategies which merit going into clinical research in Covid-19.

CK2 is a constitutively active Ser/Thr protein kinase deregulated in cancer and other pathologies, responsible for about the 20% of the human phosphoproteome [<u>17</u>, <u>18</u>]. Considering, both experimental and clinical validation data, CK2 has been regarded as an emerging oncology target [<u>19</u>, <u>20</u>]. In infectious diseases, CK2 phosphorylates and modulates the function of viral proteins from Hepatitis C Virus (HCV) [<u>21</u>], Vesicular stomatitis virus (VCV) [<u>22</u>], Human Immunodeficiency Virus (HIV) [<u>23</u>], Human

It is made available under a CC-BY-NC-ND 4.0 International license .

88 Papilloma Virus (HPV) [24], and Herpes simplex-1 (HSV-1) [25]. Furthermore, CK2 89 also regulates a number of signaling cascades such as NF- κ B [26], JAK / STAT [27], and 90 PTEN / PI3K / Akt-PKB [28], that viruses hijacked to guaranteed their propagation. 91 Therefore, it is expected that pharmacological intervention of CK2 may impact on viral 92 replication. Recently, CK2 has been found to be directly targeted by the SARS-Cov2 93 nucleocapsid protein and they both co-localize along the filopodia protrusions that 94 promote virus egress and rapid cell-to-cell spread across epithelial mono-layers of infected cells [29]. Additionally, inhibition of CK2 in those experiments demonstrated 95 96 the instrumental role of this protein kinase for SARS-Cov2 infection *in vitro* [29].

97 Considering the scientific rationality of inhibiting CK2 in SARS-Cov2 infection and 98 taking advance of CIGB-325 (formerly CIGB-300) as an anti-CK2 synthetic peptide 99 previously already assessed in different Phase I-II in cancer patients, we investigated the 100 putative clinical benefit of this peptide in Covid-19 patients. Particularly, safety and 101 tolerability of intravenous delivery of CIGB-325 has been previously assessed from 0.2 102 to 12.8 mg/kg [30, 31] as well as the consecutive-5 day regimen of administration.

In this clinical study we administered intravenous CIGB-325 at 2.5 mg/kg along with standard-of-care for treating SARS-Cov2 positive patients in Cuba which is based on alpha 2b-IFN plus kaletra/hydroxyquinoline. Preliminary data indicated that combination of CIGB-325 with standard-of-care improved chest-CT outcomes in Covid-19 patients with pneumonia at day 7. Other signs of clinical benefit for this therapeutic regimen were also registered in our study. This is the first clinical study where an anti-CK2 approach is investigated in Covid-19 disease.

It is made available under a CC-BY-NC-ND 4.0 International license .

110 Methods

111 **Patients**

112 Twenty patients confirmed as SARS-CoV-2 positive by real-time transcriptase 113 polymerase chain reaction (RT-PCR) were enrolled in an open, monocentric, randomized 114 standard-of-care controlled trial at the "Luis Diaz Soto" Hospital in Havana, Cuba 115 (https://rpcec.sld.cu/trials/RPCEC00000317-En (Code: IG/CIGB300I/CV/2001) 116 (ATENEA-Co-300 trial). CIGB-300 code was substituted by CIGB-325 just after online 117 clinical trial registration; therefore, it appears with the former code. The Ethics 118 Committee for Clinical Research in the hospital and Cuban Regulatory Agency 119 (CECMED) approved the trial. The study complied with the Good Clinical Practices and 120 the precepts established in the Declaration of the Helsinki World Medical Association. 121 All patients met the inclusion criteria described in the protocol and signed the informed 122 consent.

123 Laboratory examination

Laboratory results included blood routine, leucocyte subsets and blood biochemical parameters. Serum levels of CPK, LDH and RCP were determined by a specific Roche system (Roche-cobas-C311).

127 SARS-Cov2 viral dynamic in nasopharyngeal swabs

Nasopharyngeal swabs were obtained from patients at days 0, 3, 7, and 14. Viral RNA
was detected by RT-PCR amplification by using specific SARS-Cov2 primers. Presence
of SARS-Cov2 in swabs was followed-up at indicated times and compared among both
groups.

132 Clinical response

133 Clinical status was classified as asymptomatic, mild, moderate and severe Covid-19
134 disease according to the NIH guide "Coronavirus Disease 2019 (COVID-19) Treatment
135 guidelines". <u>https://www.covid19treatmentguidelines.nih.gov</u>. The chest-CT analysis was
136 performed considering number of pulmonary lesions, lesion's extent and common Covid137 19 typical abnormalities like consolidation, glass-round opacity and mix pattern.
138 Safety

139 Pretreatment evaluation included a detailed history and physical examination. In addition,

140 hematological counts, blood chemistry, coagulation, radiography and chest-CT studies

It is made available under a CC-BY-NC-ND 4.0 International license .

were performed. Systemic toxicity was evaluated daily after each CIGB-325
administration. Severity of adverse events was classified by the WHO Adverse Reaction
Terminology [32]. Causal relationship was classified as very probable (definitive),
probable, possible or remote (doubtful) [33].

145 Statistical Analysis

146 For chest-CT variables, the analysis was performed in Per Protocol population defined as 147 patients who completed the originally allocated and patients that have TAC at the 148 beginning and at the end of treatment. Continuous variables were expressed as mean and 149 standard deviations or median and interquartile ranges (depending of the assumption of normal distribution). Student-t test or Mann-Whitney U test were applied to continuous 150 151 variables, and chi-square or Fisher's exact test were used for categorical variables. For 152 the variation in time in each group, Wilcoxon-rank test or Student-t test for dependent variables were used. Type 1 error of 0.05 was specified. Considering the small sample 153 154 size, the difference between groups (for clinical and chest-CT evaluations, proportion of 155 patients with reduction of score and number of lesions) was estimated from the Bayesian 156 point of view, performing 10,000 simulations and specifying non-informative prior 157 distributions. The analysis was performed using SPSS 25.0 software and EPIDAT 3.1.

It is made available under a CC-BY-NC-ND 4.0 International license .

158 **Results**

159 **Baseline characteristics of Covid-19 patients**

160 Between June 1, 2020, and June 16, 2020, twenty SARS-Cov2 positive patients 161 underwent randomization in the hospital "Luis Diaz Soto" in Havana, Cuba. Ten were assigned to receive intravenous CIGB-325 + standard-of-care (Group I) and 10 to receive 162 163 standard-of-care as control (Group II). To diminish the chance of disease progression, the Cuban Program for managing Covid-19 patients is based on the application of standard-164 165 of-care immediately upon confirmation of nasopharyngeal SARS-Cov2 diagnosis irrespectively of having symptoms or not. The median number of days between SARS-166 Cov2 diagnosis, hospitalization and treatment initiation was 2 days. All the patients 167 168 completed the treatment as planned except one patient from Group I who experienced 169 some concomitant moderate histaminergic adverse events during the first CIGB-325 170 intravenous delivery and dose was decreased to 1.6 mg/kg for remaining days as 171 indicated in the clinical protocol.

The mean age of patients was 45.35 years and 70% were male (Table 1). Fourteen patients (70%) were asymptomatic at the enrollment and 9 (45%) at the starting day of treatment. Fifty percent of patients (5/10) had moderate disease and 20% (2/10) were severe in the CIGB-325 group while 40% of patients (4/10) had moderate disease and none severe case at the starting day of treatment (Table 1).

Overall, 25% of patients had hypertension, 25% had obesity and none had type 2 diabetes. Other comorbidities were anemia (1/20), glaucoma (1/20), hypothyroidism (1/20), cancer (1/20). The most substantial imbalance in baseline characteristics was observed between the CIGB-325 group and control respect to age and coexisting high risk conditions which were more unfavorable in the CIGB-325 group (Table 1).

Data from baseline chest-CT analysis showed that 80% of patients in the CIGB-325 group had positive chest-CT according to presence of ground-glass opacity, consolidation, mixed pattern and affectation of more than three pulmonary lobules. In the control group, 50% of patients had positive chest-CT with presence of consolidation, mixed pattern and affectation of less than two pulmonary lobules.

187 Concerning hematological and biochemical baseline parameters in all patients, abnormal
188 levels were observed in hemoglobin (25%), platelets (15%), neutrophils (50%),

It is made available under a CC-BY-NC-ND 4.0 International license .

- 189 lymphocytes (40%), aspartate aminotransferase (ASAT) (20%), alanine aminotransferase
- 190 (ALAT)(40%), ferritin (35%), creatinine (20%), and glycemia (30%). Other parameters
- 191 were in the normal range.

192 **Primary and exploratory efficacy end points**

The dynamic conversion from positive to negative of SARS-Cov2 RT-PCR results was analyzed in both groups of treatments at 0, 3, 7, and 14 days. No significant differences were observed in the median time, 11 days \pm 8.0 for CIGB-325 plus standard care and 12 days \pm 6 for standard care alone (p = 0.614). Thus, time to SARS-Cov2 viral clearance in the nasopharynx swabs behaved similarly for both treatments over the time.

198 The clinical status was classified in categories of asymptomatic, mild, moderate or severe 199 disease and it was followed up until ending treatment and thereafter for both groups. In 200 the intent-to-treat population of CIGB-325 group at day 6 there were 2/10 patients that 201 remained asymptomatic since initiation of treatment, 2/10 changed from severe to 202 moderate, 1/10 from moderate to asymptomatic, 1/10 from mild to asymptomatic and 203 4/10 did not change their clinical status during the treatment. Otherwise, in the control 204 6/10 patients remained asymptomatic since initiation of treatment, 1/10 changed from 205 mild to asymptomatic and 3/10 did not change their clinical status during the treatment.

Additionally, chest-CT analysis was performed to investigate the effect of CIGB-325 206 207 over the Covid-19 pulmonary lesions. For that purpose, both number and lesion's extent 208 at day 0 and after treatment (day 7) were compared just in those patients analyzed per 209 protocol (Table 2). Importantly, CIGB-325 treatment significantly reduced the median 210 number of pulmonary lesions from 9.5 \pm 10 (day 0) to 5.5 \pm 10 (day 7) (p = 0.042). 211 Conversely, no substantial change was observed in the control group. Proportion of 212 patients with reduction of pulmonary lesions was higher in the CIGB-325 group 213 compared with control according to the Bayesian analysis (pDif > 0; 0.951) (Table 2).

The effect over lesion's extent showed in Table 3 including those patients analyzed per protocol indicates that CIGB-325 treatment also reduced the median of lesion's extent after consecutive-5 day regimen although not significantly. Otherwise, any kind of reduction was observed in the control group. Importantly, proportion of patients with reduction of lesion's extent was higher in the CIGB-325 group (4/7) compared with control (1/9) (pDif > 0; 0.982) (Bayesian analysis).

It is made available under a CC-BY-NC-ND 4.0 International license .

220 The overall chest-CT response was also analyzed considering the number of lesions, lesion's extent and the pattern of Covid-19 typical chest-CT abnormalities (Table 4). The 221 222 analysis per protocol showed that 50% (3/6) of patients in the CIGB-325 group had a 223 favorable overall chest-CT response compared with 28.6% (2/7) in the control (pDif > 0; 224 0.796) (Bayesian analysis). Importantly, any patient had progression in the CIGB-325 225 group and 28.6% (2/7) in the control group did it. Representative images of chest-CT 226 evolution from one CIGB-325 treated patient are shown in Figure 1. 227 High levels of different serum markers like Creatinine Phospho Kinase (CPK), Reactive

228 C-Protein (RCP), and Lactate dehydrogenase (LDH) have been associated to the adverse

229 clinical outcome in Covid-19 patients. Therefore, we also explored the effect of CIGB-

230 325 over these markers as secondary measure of efficacy. Of note, data from Figure 2

shows that CIGB-325 treatment significantly reduced the CPK (p = 0.007) and LDH (p =

0.028) serum levels. Also, the RCP values were lowered by CIGB-325 although with no

- 233 statistical difference.
- 234 Safety

Data from safety analysis indicated that intravenous CIGB-325 added to standard-*of*-care did increase both frequency of adverse events and patients with adverse events (Table 5). Particularly, pruritus, flushing and rash were increased by CIGB-325 treatment in the 100, 80 and 60 % of patients respectively. As previously observed during CIGB-325 intravenous administration, intensity of this kind of adverse events was mild and/or moderate in all of the patients.

It is made available under a CC-BY-NC-ND 4.0 International license .

241 **Discussion**

Protein Kinase CK2 has been recently suggested as a relevant target to combat SARS-Cov2 infection because of its role on the viral particles egress once accumulated in filopodial protrusions possessing budding viral particles [29]. Although anti-SARS-Cov2 activity has been demonstrated through *in vitro* models by inhibiting protein kinase CK2, consistent and compelling evidence for effective anti-CK2 drugs from clinical studies is not available at this.

248 CIGB-325 is an anti-CK2 synthetic peptide extensively assessed in cancer patients whose 249 safety, tolerability and efficacy signs have been gathered from Phase I-II trials. This 250 clinical trial investigated the short-term outcomes of intravenous CIGB-325 at 2.5 mg/kg 251 in a consecutive-5 day regimen which was added to standard care used in Covid-19 252 disease in Cuba. Preliminary results suggest a quick clinical benefit with CIGB-325 253 treatment particularly evidenced by the chest-CT data at day 7 post-treatment initiation. 254 Despite the limited sample size and the imbalance of the baseline patient's characteristics unfavorable for the CIGB-325 group, our trial found that this treatment regimen had 255 256 clinical benefit for Covid-19 patients with lower respiratory tract involvement. 257 Specifically, CIGB-325 treatment fostered reduction of both, the number pulmonary 258 lesions, and lesion's extent at day 7. Likewise, proportion of patients exhibiting this 259 inhibitory effect is superior in the CIGB-325 group compared with standard care. When 260 overall chest-CT response was analyzed by gathering number of lesions, lesion's extent 261 and the pattern of Covid-19 typical abnormalities, 50% of patients in the CIGB-325 262 group had favorable outcome compared with 20% in the standard care. The odds of 263 difference for the CIGB-325 treatment respect standard care were > 0.90 in all the chest-264 CT data by using a Bayesian model.

Considering some specific Covid-19 pulmonary lesions haven been associated to direct SARS-Cov2 infection of pneumocytes [34] along with the instrumental role of CK2 during such infection [29], it might be reasonable to think that reduction of lesions can be achieved by an antiviral activity of CIGB-325 *onsite*. In fact, previous preclinical data of CIGB-325 pharmacokinetics and distribution in mice have demonstrated that up to 7.5 mg/kg of peptide lung uptake is achieved after intravenous delivery [35].

It is made available under a CC-BY-NC-ND 4.0 International license .

This quick improvement of chest-CT response encouraged by addition of CIGB-325 to standard care could have a great clinical impact in avoiding progression to severity of Covid-19 patients. Additionally, our study shows that standard care based on alpha 2b IFN + kaletra/hydroxychloroquine also reduces pulmonary lesions at day 7 although to a lesser extent. Such effect rather might be by the previously reported anti-SARS-Cov2 activity of type I IFNs when administered either by parenteral route or inhaled [36].

277 While the clinical status (in particular SpO2 levels) and concurrent comorbidities of 278 COVID-19 patients largely determine the need for their admittance to Intensive Care 279 Units, several laboratory parameters may facilitate the assessment of disease severity and 280 rational triaging. Among the markers that may be used in risk stratification to predict 281 severe and fatal COVID-19 in hospitalized patients are the high serum levels of CPK 282 [37], CRP [38] and LDH [39]. We found that CIGB-325 treatment decreased 283 significantly the CPK levels compared with standard care which can suggest an early 284 protective effect from tissue damage. High serum CPK levels have been associated to 285 rhabdomyolysis, weakness and heart injury in Covid-19 patients; therefore, these findings 286 also support the clinical benefit of using CIGB-325 in this viral disease. Accordingly, 287 LDH and CRP serum levels which are considered inflammatory markers were also 288 reduced after CIGB-325 treatment although no significantly.

Improvement of the clinical status at day 7 also trended to be superior by adding CIGB-325 to the standard care where 50% (4/8) patients experienced change towards a more favorable clinical category. Otherwise, standard care alone improved clinical status in 25% (1/4). However, as this analysis takes into account only symptomatic patients in both groups, confirmation of the CIGB-325 effect in larger size population must be of major priority in future studies of this anti-CK2 peptide in Covid-19.

The dynamic conversion from positive to negative of SARS-Cov2 RT-PCR at the nasopharyngeal swabs was very similar for both groups of treatments over the time. Addition of CIGB-325 to the standard care did not shorten the time to viral clearance respect to the standard care at least in the regimen tested in our clinical trial. Other protocols with higher frequency of CIGB-325 administration merit to be explored for that purpose in future trials. Nonetheless, the usefulness and feasibility of the viral end point

It is made available under a CC-BY-NC-ND 4.0 International license .

301 in nasopharyngeal swabs to assess anti-SARS-Cov2 drugs has not been established yet.

302 Instead, clinical endpoints seem to be more informative in the Covid-19 disease [11, 15].

The safety profile of CIGB-325 plus standard care was very similar to that observed for CIGB-325 alone in which a predominant pattern of transient histaminergic-like side effects has been observed [30]. However, intensity of the side effects was mild and/or moderate in all the patients and total resolution of them was achieved in no more than one hour after CIGB-325 administration. Thus, our study confirms that combination of intravenous CIGB-325 at 2.5 mg/kg with standard care for Covid-19 is a manageable and safe strategy to treat patients with this infectious disease.

All in all, our study gave important clues suggesting a potential quick clinical benefit at day 7 by using our anti-CK2 approach which has not been reported so far in Covid-19. Recently, a clinical trial with RDV has reported clinical benefit in terms of the number of days to recovery of the hospitalized Covid-19 patients with lower respiratory tract involvement in 11 days (95% confidence interval [CI], 9 to 12), [15], however evidences of chest-CT improvement at day 7 were not provided.

Finally, integration of our data leads to the speculation that CIGB-325 might prevent COVID-19 getting worse by inducing an antiviral effect in the lungs and preventing damage caused by the virus. This notion merits further verification in future larger clinical trials of CIGB-325 in Covid-19 patients.

320 Limitations

321 In this exploratory study with a small sample size, randomization allowed a balance 322 between the groups regarding the allocation of treatments but not regarding the 323 prognostic variables.

It is made available under a CC-BY-NC-ND 4.0 International license .

324 Conclusions

325 Combination of CIGB-325 anti-CK2 peptide with standard-of-care based on alpha 2b-326 IFN/kaletra/hydroxychloroquine was adequately tolerated and superior in improving a 327 quick chest-CT response in Covid-19 patients. On the contrary, SARS-Cov2 dynamics in 328 nasopharyngeal swabs was similar for both groups over the time. Our clinical findings 329 support future studies to continue to improve patient outcomes in Covid-19 by optimizing 330 CIGB-325 regimens and combining with other antiviral agents. This is the first clinical 331 study using an anti-CK2 approach in Covid-19 and our findings suggest that CK2 332 inhibition can be an antiviral strategy with favorable risk-benefit to fight SARS-Cov2

333 infection.

It is made available under a CC-BY-NC-ND 4.0 International license .

334 Statements

335 Acknowledgements

We thank Rosa Martinez, Manuel Puerto, Daimays González, Yahima de la O Tamayo, Dianelis
Pérez- Malo, Estela A Deyvis, Yuilyns Morales, Caridad Aguirre, and Yuliet Sinclair for their
logistic support at the Luis Diaz Soto Hospital. Also, we thank Elizeth García, José Luis

339 Rodriguez, Grettel Melo, Reinier Hernandez, Marel Alonso, Julio E Baldomero, and Francisco

340 Hernandez from Clinical Department at the CIGB for their great contribution in the clinical trial

341 execution.

342 **Conflict of Interest**

343 The authors declare no conflict of interest.

344 Appendix

- 345 ATENEA-Co-300 group: Idelsis Esquivel, Maura García, Sara M Martínez, Ana G Galarraga,
- 346 Kenia Gómez, Sidalyn Gutiérrez, Maria E Fuerte, Jane Fernandez, Yose Gamallo, Yanelis
- 347 Alvarez, Yarelis Amador, Reynier Perez, Lisset Perurena, Daylen Aguilar

It is made available under a CC-BY-NC-ND 4.0 International license .

348 **References:** 349 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200809-covid-19-1. 350 sitrep-202. 351 2. https://coronavirus.jhu.edu/map.html. 352 3. Cohen, P. A.; Hall, L.; John, J. N.; Rapoport, A. B. In The early natural history of SARS-CoV-2 353 infection: Clinical observations from an urban, ambulatory COVID-19 clinic, Mayo Clinic 354 Proceedings, 2020; Elsevier: 2020; pp 1124-1126. 355 4. Wu, Z.; McGoogan, J., Outbreak in China: Summary of a Report of 72314 Cases from the Chinese 356 Center for Disease Control and Prevention. JAMA 2020, 10. 357 5. Wu, J.; Mafham, M.; Mamas, M.; Rashid, M.; Kontopantelis, E.; Deanfield, J.; de Belder, M.; 358 Gale, C. P., Place and underlying cause of death during the COVID19 pandemic: retrospective 359 cohort study of 3.5 million deaths in England and Wales, 2014 to 2020. medRxiv 2020. 360 6. Phillips, R. O.; Robert, J.; Abass, K. M.; Thompson, W.; Sarfo, F. S.; Wilson, T.; Sarpong, G.; 361 Gateau, T.; Chauty, A.; Omollo, R., Rifampicin and clarithromycin (extended release) versus 362 rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-363 inferiority phase 3 trial. The Lancet 2020. 364 7. Pushpakom, S.; Iorio, F.; Eyers, P. A.; Escott, K. J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, 365 T.; Latimer, J.; McNamee, C., Drug repurposing: progress, challenges and recommendations. 366 *Nature reviews Drug discovery* **2019**, 18, (1), 41-58. 367 8. Ohashi, H.; Watashi, K.; Saso, W.; Shionoya, K.; Iwanami, S.; Hirokawa, T.; Shirai, T.; Kanaya, 368 S.; Ito, Y.; Kim, K. S., Multidrug treatment with nelfinavir and cepharanthine against COVID-19. 369 bioRxiv 2020. 370 9. Bao, L.; Deng, W.; Gao, H.; Xiao, C.; Liu, J.; Xue, J.; Lv, Q.; Liu, J.; Yu, P.; Xu, Y., Lack of 371 reinfection in rhesus macaques infected with SARS-CoV-2. bioRxiv 2020. 372 10. Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M., A 373 trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. New England Journal of 374 *Medicine* **2020***.* 375 11. Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q., 376 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled,

multicentre trial. The Lancet 2020.

377

Borba, M. G. S.; Val, F. F. A.; Sampaio, V. S.; Alexandre, M. A. A.; Melo, G. C.; Brito, M.;
Mourão, M. P. G.; Brito-Sousa, J. D.; Baía-da-Silva, D.; Guerra, M. V. F., Effect of high vs low
doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. *JAMA network open* 2020, 3, (4), e208857-e208857.

- Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y.,
 Experimental treatment with favipiravir for COVID-19: an open-label control study. *Engineering*2020.
 Bauchner, H.; Fontanarosa, P. B., Randomized clinical trials and COVID-19: managing
 expectations. *Jama* 2020.
- Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C.;
 Hohmann, E.; Chu, H. Y.; Luetkemeyer, A.; Kline, S., Remdesivir for the treatment of Covid19—preliminary report. *New England Journal of Medicine* 2020.
- Ahidjo, B. A.; Loe, M.; Ng, Y. L.; Mok, C. K.; Chu, J. J. H., Current Perspective of Antiviral
 Strategies against COVID-19. *ACS Infectious Diseases* 2020.
- 393 17. Perera, Y.; Ramos, Y.; Padrón, G.; Caballero, E.; Guirola, O.; Caligiuri, L. G.; Lorenzo, N.;
 394 Gottardo, F.; Farina, H. G.; Filhol, O., CIGB-300 anti-cancer peptide regulates the protein kinase
 395 CK2-dependent phosphoproteome. *Mol Cell Biochem* 2020.
- Chua, M. M.; Ortega, C. E.; Sheikh, A.; Lee, M.; Abdul-Rassoul, H.; Hartshorn, K. L.;
 Dominguez, I., CK2 in cancer: cellular and biochemical mechanisms and potential therapeutic
 target. *Pharmaceuticals* 2017, 10, (1), 18.
- Siddiqui-Jain, A.; Drygin, D.; Streiner, N.; Chua, P.; Pierre, F.; O'Brien, S. E.; Bliesath, J.; Omori,
 M.; Huser, N.; Ho, C., CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2,
 inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. *Cancer research*2010, 70, (24), 10288-10298.
- Laudet, B.; Barette, C.; Dulery, V.; Renaudet, O.; Dumy, P.; Metz, A.; Prudent, R.; Deshiere, A.;
 Dideberg, O.; Filhol, O., Structure-based design of small peptide inhibitors of protein kinase CK2
 subunit interaction. *Biochemical Journal* 2007, 408, (3), 363-373.
- Tellinghuisen, T. L.; Foss, K. L.; Treadaway, J., Regulation of hepatitis C virion production via
 phosphorylation of the NS5A protein. *PLoS Pathog* 2008, 4, (3), e1000032.
- 408 22. Gupta, A. K.; Das, T.; Banerjee, A. K., Casein kinase II is the P protein phosphorylating cellular
 409 kinase associated with the ribonucleoprotein complex of purified vesicular stomatitis virus.
 410 *Journal of general virology* 1995, 76, (2), 365-372.
- 411 23. Meggio, F.; D'Agostino, D. M.; Ciminale, V.; Chieco-Bianchi, L.; Pinna, L. A., Phosphorylation
 412 of HIV-1 Rev protein: implication of protein kinase CK2 and pro-directed kinases. *Biochemical*413 *and biophysical research communications* 1996, 226, (2), 547-554.
- 414 24. Firzlaff, J.; Galloway, D.; Eisenman, R.; Lüscher, B., The E7 protein of human papillomavirus
 415 type 16 is phosphorylated by casein kinase II. *The New biologist* 1989, 1, (1), 44-53.
- 416 25. Smith, M. C.; Bayless, A. M.; Goddard, E. T.; Davido, D. J., CK2 inhibitors increase the
 417 sensitivity of HSV-1 to interferon-β. *Antiviral research* 2011, 91, (3), 259-266.
- 418 26. Trembley, J. H.; Wang, G.; Unger, G.; Slaton, J.; Ahmed, K., Protein kinase CK2 in health and
 419 disease. *Cellular and molecular life sciences* 2009, 66, (11-12), 1858-1867.

420	27.	Zheng, Y., A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway:
421		implications for cancer biology. Journal of Interferon & Cytokine Research 2011, 31, (2), 265-
422		267.
423	28.	Di Maira, G.; Salvi, M.; Arrigoni, G.; Marin, O.; Sarno, S.; Brustolon, F.; Pinna, L.; Ruzzene, M.,
424		Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death & Differentiation 2005,
425		12, (6), 668-677.
426	29.	Bouhaddou, M.; Memon, D.; Meyer, B.; White, K. M.; Rezelj, V. V.; Marrero, M. C.; Polacco, B.
427		J.; Melnyk, J. E.; Ulferts, S.; Kaake, R. M., The global phosphorylation landscape of SARS-CoV-
428		2 infection. Cell 2020, 182, (3), 685-712. e19.
429	30.	García-Diegues, R.; de la Torre-Santos, A., Phase I Study of CIGB-300 Administered
430		Intravenously in Patients with Relapsed/Refractory Solid Tumors. ARCHIVOS DE MEDICINA
431		2018, 1, (1), 4.
432	31.	Fernández Águila, J. D.; García Vega, Y.; Ríos Jiménez, R. O.; López Sacerio, A.; Rodríguez
433		Rodríguez, C. R.; Rodríguez Fraga, Y.; Valenzuela Silva, C., Safety of intravenous application of
434		cigb-300 in patients with hematological malignancies. EHPMA study. Revista Cubana de
435		Hematología, Inmunología y Hemoterapia 2016, 32, (2), 236-248.
436	32.	https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40.
437	33.	https://www.who-umc.org/whodrug/whodrug-portfolio.
438	34.	Carsana, L.; Sonzogni, A.; Nasr, A.; Rossi, R. S.; Pellegrinelli, A.; Zerbi, P.; Rech, R.; Colombo,
439		R.; Antinori, S.; Corbellino, M., Pulmonary post-mortem findings in a series of COVID-19 cases
440		from northern Italy: a two-centre descriptive study. The Lancet Infectious Diseases 2020.
441	35.	Perera, Y.; Farina, H. G.; Hernández, I.; Mendoza, O.; Serrano, J. M.; Reyes, O.; Gómez, D. E.;
442		Gómez, R. E.; Acevedo, B. E.; Alonso, D. F., Systemic administration of a peptide that impairs
443		the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. International
444		<i>journal of cancer</i> 2008, 122, (1), 57-62.
445	36.	Pereda, R.; Gonzalez, D.; Rivero, H. B.; Rivero, J. C.; del Rosario Lopez, L.; Mezquia, N.;
446		Venegas, R.; Betancourt, J. R.; Dominguez, R. E., Therapeutic effectiveness of interferon alpha 2b
447		treatment for COVID-19 patient recovery. medRxiv 2020.
448	37.	Chan, K. H.; Farouji, I.; Harnoud, A. A.; Slim, J., Weakness and elevated creatinine kinase as the
449		initial presentation of coronavirus disease 2019 (COVID-19). The American Journal of
450		Emergency Medicine 2020 .
451	38.	Velavan, T. P.; Meyer, C. G., Mild versus severe COVID-19: laboratory markers. International
452		Journal of Infectious Diseases 2020.
453	39.	Henry, B. M.; Aggarwal, G.; Wong, J.; Benoit, S.; Vikse, J.; Plebani, M.; Lippi, G., Lactate
454		dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A
455		pooled analysis. The American Journal of Emergency Medicine 2020.
456		

- 457 Legends Figures
- 458 Figure 1: Chest-CT Evolution.
- 459 Representative chest-CT images from one patient in the CIGB-325 group at day 0 and
- 460 day 7.
- 461 Figure 2: Serum levels of Covid-19 linked markers.
- 462 Serum levels of CPK (A), RCP (B) and LDH (C). Group I: CIGB-325 + Standard-of-
- 463 care. Group II: Standard-of-care.

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1: Chest-CT Evolution

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 2: Serum levels of Covid-19 linked markers.

Table 1. Demographic and Clinical Characteristics at Baseline						
Characteristic	All CIGB-325 + (N=20) Standard Care (N=10)		Standard Care (N=10)			
Age (years)	45.35±12.0	51.6±11.4	39.1±12.6			
Sex No. (%) Male	14 (70)	8 (80)	6 (60)			
Female	6 (30)	2 (20)	4 (40)			
Skin color No. (%)						
White	12 (60)	5 (50)	7 (70)			
Mestizo	2 (20)	1 (10)	1 (10)			
Black	6 (20)	4 (40)	2 (20)			
Coexisting conditions No./Total No. (%)						
Hypertension	5 (25)	5 (50)	0 (0.0)			
Obesity	5 (25)	2 (20)	3 (30)			
Type 2 Diabetes	0 (0.0)	0 (0.0)	0 (0.0)			
Cancer	1 (5)	1 (10)	0 (0.0)			
Iron deficiency Anemia	1 (5)	0 (0.0)	1 (10)			
Hypothyroidism	1 (5)	0 (0.0)	1 (10)			
Glaucoma	1 (5)	0 (0.0)	1 (10)			
Clinical status at						
enrollment						
Asymptomatic	14 (70)	6 (60)	8 (80)			
Symptomatic	6 (20)	4 (40)	2 (20)			
Clinical status at the starting day of treatment						
Asymptomatic	9 (45)	3 (30)	6 (60)			
Mild	0 (0.0)	0 (0.0)	0 (0.0)			
Moderate	9 (45)	5 (50)	4 (40)			
Severe	2 (10)	2 (20)	0 (0.0)			
Symptoms						
Headache	3 (15)	2 (20)	1 (10)			
Anosmia	1 (5)	0 (0.0)	1 (10)			
Loss of taste	1 (5)	0 (0.0)	1 (10)			
Fever	2 (10)	2 (20)	0 (0.0)			
Dry cough	2 (10)	1 (10)	1 (10)			
Loss of appetite	1 (5)	1 (10)	0 (0.0)			
Shortness of breath	1 (5)	0 (0.0)	1 (10)			
Diarrhea	1 (5)	1 (10)	0 (0.0)			

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2: Chest-CT evolution considering number of pulmonary lesions							
		Group	Ι	II	Sign. (U-		
		N*	6	7	Mann		
					Whitney)		
		Median $\pm RI$	9.5 ± 10.0	3.0 ± 5.0	0.051		
Number of losions	Day 0	(Min; Max)	(0; 18)	(0; 10)			
Number of lesions		Median $\pm RI$	5.5 ± 10.0	2.0 ± 5.0	0.149		
	Day 7	(Min; Max)	(0; 17)	(0; 6)			
		Sign. (Wilcoxon)	0.042	0.680			
Reduction of lesions		YES	5 (83.3%)	3 (42.9%)	0.266		
		NO	1 (16.7%)	4 (57.1%)	(Fisher)		
		Dif. (IC 95%)	Dif. (IC 95%) 41.4 (-6.9; 78.6)		Bayesian		
		P (Dif.>0)	0.951		analysis		

* Per protocol population defined as patients who completed the originally allocated and patients that have TAC at the beginning and at the end of treatment.

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 3: Chest-CT evolution considering lesion's extent							
		Group	Ι	II	Sign. (U-		
		N*	7	9	Mann		
					Whitney)		
	Day 0	Median $\pm RI$	4.5 ± 10.0	2.0 ± 5.0	0.146		
Lesion's extent		(Min; Max)	(0; 18)	(0; 6)			
(Score 1-5)	Day 7	Median ± RI	3.5 ± 10.0	2.0 ± 3.0	0.189		
		(Min; Max)	(0; 15)	(0; 6)			
		Sign. (Wilcoxon)	0.066	1.000			
Reduction of lesion's extent		YES	4 (66.7%)	1 (14.3%)	0.103		
		NO	2 (33.0%)	6 (85.7%)	(Fisher)		
		Dif. (IC 95%)	Dif. (IC 95%) 53.2 (3.6; 86.8)		Bayesian		
		P (Dif.>0)	0.98	82	analysis		

* Per protocol population defined as patients who completed the originally allocated and patients that have TAC at the beginning and at the end of treatment

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 4: Overall chest-CT response							
	Group	Ι			Sig.		
	N	Frequency 10	% 100.0	Frequency 10	% 100.0	(Fisher)	
Chest-CT	N*	6	60.0	7	70.0		
response	Responders	3	50.0	2	28.6	0.592	
	No progression	1	16.7	2	28.6		
	Stable	2	33.3	1	14.3		
	Progression	0	0.0	2	28.6		
	Dif. (IC 95%)		Bayesian				
	P (Dif.>0)		analysis				
* Per protocol population defined as patients who completed the originally allocated and patients							

that have TAC at the beginning and at the end of treatment.

Table 5: Adverse events									
	Group I				Group II				
	Patients		Ever	Events		Patients		Events	
	Frequency	%	Frequency	%	Frequency	%	Frequency	%	
Ν	10	100	109	100	10	100	7	100	
Pruritus	10	100.0	48	44.0					
Rash	6	60.0	12	11.0					
Flush	8	80.0	23	21.1					
Hot flashes	5	50.0	12	11.0					
Wheals	3	30.0	5	4.6					
Bradycardia	1	10.0	1	0.9					
Cramps	2	20.0	2	1.8	1	10.0	1	14.3	
Trembling	2	20.0	2	1.8					
Chills	1	10.0	1	0.9					
Nausea	1	10.0	1	0.9	1	10.0	2	28.6	
Tinnitus	1	10.0	2	1.8					
Diarrhea					1	10.0	2	28.6	
Headache					1	10.0	2	28.6	
Group I: CIGB	-325 plus stand	ard-of-ca	are Group	II: Star	dard-of-care				